Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grand SLAM
NCT06488482Phase 3Recruiting
- Sponsor
- Uppsala University
- Start
- Dec 2024
- Primary completion
- Sep 2030
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of nivolumab and pembrolizumab in Malignant Melanoma (MM) (2 arms), sponsored by Uppsala University. Primary endpoints: Distant Metastatic-Free Survival at 2 years and Relapse-Free Survival at 2 years. Started Dec 2024; status: recruiting.
02
Drugs
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT06488482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06488482.